{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T12:46:19Z","timestamp":1791636379408,"version":"4.3.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,3]]},"DOI":"10.7759\/cureus.100683","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T14:23:43Z","timestamp":1767450223000},"source":"Crossref","is-referenced-by-count":1,"title":["Successful Reintroduction of Golimumab in a Patient With Rheumatoid Arthritis and Prolonged Epstein-Barr Virus Reactivation With Persistent Anti-Viral Capsid Antigen IgM Antibodies: A Case Report"],"prefix":"10.7759","author":[{"given":"Daiki","family":"Fujimori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haeru","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Shoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuji","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)01525-8","article-title":"Rheumatoid arthritis","volume":"402","author":"Di Matteo A","year":"2023","unstructured":"Di Matteo A, Bathon JM, Emery P. Rheumatoid arthritis. Lancet. 2023, 402:2019-33. 10.1016\/s0140-6736(23)01525-8","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow SH","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, et al.. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016, 127:2375-90. 10.1182\/blood-2016-01-643569","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12116","article-title":"Methotrexate\/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression","volume":"91","author":"Ichikawa A","year":"2013","unstructured":"Ichikawa A, Arakawa F, Kiyasu J, et al.. Methotrexate\/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013, 91:20-8. 10.1111\/ejh.12116","journal-title":"Eur J Haematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/art.42809","article-title":"Effect of recent antirheumatic drug on features of rheumatoid arthritis-associated lymphoproliferative disorders","volume":"76","author":"Hoshida Y","year":"2024","unstructured":"Hoshida Y, Tsujii A, Ohshima S, et al.. Effect of recent antirheumatic drug on features of rheumatoid arthritis-associated lymphoproliferative disorders. Arthritis Rheumatol. 2024, 76:869-81. 10.1002\/art.42809","journal-title":"Arthritis Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.08.026","article-title":"Epstein-Barr virus: biology and clinical disease","volume":"185","author":"Damania B","year":"2022","unstructured":"Damania B, Kenney SC, Raab-Traub N. Epstein-Barr virus: biology and clinical disease. Cell. 2022, 185:3652-70. 10.1016\/j.cell.2022.08.026","journal-title":"Cell"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000787","article-title":"Epstein-Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes","volume":"34","author":"Lindsay J","year":"2021","unstructured":"Lindsay J, Othman J, Heldman MR, Slavin MA. Epstein-Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes. Curr Opin Infect Dis. 2021, 34:635-45. 10.1097\/QCO.0000000000000787","journal-title":"Curr Opin Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13719","article-title":"Dynamics of Epstein-Barr virus on post-transplant lymphoproliferative disorders after antithymocyte globulin-conditioned allogeneic hematopoietic cell transplant","volume":"23","author":"Lindsay J","year":"2021","unstructured":"Lindsay J, Othman J, Yong MK, et al.. Dynamics of Epstein-Barr virus on post-transplant lymphoproliferative disorders after antithymocyte globulin-conditioned allogeneic hematopoietic cell transplant. Transpl Infect Dis. 2021, 23:e13719. 10.1111\/tid.13719","journal-title":"Transpl Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13731","article-title":"The impact of chronic Epstein-Barr virus infection on the liver graft of pediatric liver transplant recipients: a retrospective observational study","volume":"23","author":"Shizuku M","year":"2021","unstructured":"Shizuku M, Kamei H, Yoshizawa A, et al.. The impact of chronic Epstein-Barr virus infection on the liver graft of pediatric liver transplant recipients: a retrospective observational study. Transpl Infect Dis. 2021, 23:e13731. 10.1111\/tid.13731","journal-title":"Transpl Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2024.100837","article-title":"Post-transplant lymphoproliferative disorders following kidney transplantation: a literature review with updates on risk factors, prognostic indices, screening strategies, treatment and analysis of donor type","volume":"38","author":"Ergisi M","year":"2024","unstructured":"Ergisi M, Ooi B, Salim O, Papalois V. Post-transplant lymphoproliferative disorders following kidney transplantation: a literature review with updates on risk factors, prognostic indices, screening strategies, treatment and analysis of donor type. Transplant Rev (Orlando). 2024, 38:100837. 10.1016\/j.trre.2024.100837","journal-title":"Transplant Rev (Orlando)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh313","article-title":"Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas","volume":"96","author":"Feng WH","year":"2004","unstructured":"Feng WH, Cohen JI, Fischer S, et al.. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst. 2004, 96:1691-702. 10.1093\/jnci\/djh313","journal-title":"J Natl Cancer Inst"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/ar1893","article-title":"Epstein-Barr virus and rheumatoid arthritis: is there a link?","volume":"8","author":"Costenbader KH","year":"2006","unstructured":"Costenbader KH, Karlson EW. Epstein-Barr virus and rheumatoid arthritis: is there a link?. Arthritis Res Ther. 2006, 8:204. 10.1186\/ar1893","journal-title":"Arthritis Res Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/530568","article-title":"Epstein-barr virus reactivation after infliximab in rheumatoid arthritis: a case report","volume":"2011","author":"Colaci M","year":"2011","unstructured":"Colaci M, Sebastiani M, Sandri G, Meacci M, Ferri C. Epstein-barr virus reactivation after infliximab in rheumatoid arthritis: a case report. Case Rep Infect Dis. 2011, 2011:530568. 10.1155\/2011\/530568","journal-title":"Case Rep Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3641813","article-title":"Reactivation of Epstein-Barr virus presenting as massive splenomegaly after initiation of golimumab treatment","volume":"2020","author":"Febres-Aldana AJ","year":"2020","unstructured":"Febres-Aldana AJ, Febres-Aldana CA, Dvir K, Galarza-Fortuna G, Schwartz M, Medina AM, Sriganeshan V. Reactivation of Epstein-Barr virus presenting as massive splenomegaly after initiation of golimumab treatment. Case Rep Hematol. 2020, 2020:3641813. 10.1155\/2020\/3641813","journal-title":"Case Rep Hematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-023-03660-5","article-title":"Updated guidelines for chronic active Epstein-Barr virus disease","volume":"118","author":"Kawada JI","year":"2023","unstructured":"Kawada JI, Ito Y, Ohshima K, et al.. Updated guidelines for chronic active Epstein-Barr virus disease. Int J Hematol. 2023, 118:568-76. 10.1007\/s12185-023-03660-5","journal-title":"Int J Hematol"},{"key":"ref15","article-title":"Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication","volume":"34","author":"Hoshida Y","year":"2007","unstructured":"Hoshida Y, Xu JX, Fujita S, et al.. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol. 2007, 34:322-31.","journal-title":"J Rheumatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1996.d01-735.x","article-title":"Analysis of V kappa genes in rheumatoid arthritis (RA) synovial B lymphocytes provides evidence for both polyclonal activation and antigen-driven selection","volume":"105","author":"Moyes SP","year":"1996","unstructured":"Moyes SP, Brown CM, Scott BB, Maini RN, Mageed RA. Analysis of V kappa genes in rheumatoid arthritis (RA) synovial B lymphocytes provides evidence for both polyclonal activation and antigen-driven selection. Clin Exp Immunol. 1996, 105:89-98. 10.1046\/j.1365-2249.1996.d01-735.x","journal-title":"Clin Exp Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-56279-0","article-title":"Rheumatoid arthritis patients display B-cell dysregulation already in the na\u00efve repertoire consistent with defects in B-cell tolerance","volume":"9","author":"Wang Y","year":"2019","unstructured":"Wang Y, Lloyd KA, Melas I, et al.. Rheumatoid arthritis patients display B-cell dysregulation already in the na\u00efve repertoire consistent with defects in B-cell tolerance. Sci Rep. 2019, 9:19995. 10.1038\/s41598-019-56279-0","journal-title":"Sci Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780251210","article-title":"Quantitation of cells secreting rheumatoid factor of IgG, IgA, and IgM class after elution from rheumatoid synovial tissue","volume":"25","author":"Egeland T","year":"1982","unstructured":"Egeland T, Lea T, Saari G, Mellbye OJ, Natvig JB. Quantitation of cells secreting rheumatoid factor of IgG, IgA, and IgM class after elution from rheumatoid synovial tissue. Arthritis Rheum. 1982, 25:1445-50. 10.1002\/art.1780251210","journal-title":"Arthritis Rheum"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/art.22279","article-title":"Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response","volume":"54","author":"Verpoort KN","year":"2006","unstructured":"Verpoort KN, Jol-van der Zijde CM, Papendrecht-van der Voort EA, et al.. Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum. 2006, 54:3799-808. 10.1002\/art.22279","journal-title":"Arthritis Rheum"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2024.2321700","article-title":"Immunoglobulin G\/immunoglobulin M autoantibody ratios in incomplete systemic lupus erythematosus","volume":"53","author":"Henning S","year":"2024","unstructured":"Henning S, Westra J, Roozendaal C, et al.. Immunoglobulin G\/immunoglobulin M autoantibody ratios in incomplete systemic lupus erythematosus. Scand J Rheumatol. 2024, 53:207-16. 10.1080\/03009742.2024.2321700","journal-title":"Scand J Rheumatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/429287-successful-reintroduction-of-golimumab-in-a-patient-with-rheumatoid-arthritis-and-prolonged-epstein-barr-virus-reactivation-with-persistent-anti-viral-capsid-antigen-igm-antibodies-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T14:23:44Z","timestamp":1767450224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/429287-successful-reintroduction-of-golimumab-in-a-patient-with-rheumatoid-arthritis-and-prolonged-epstein-barr-virus-reactivation-with-persistent-anti-viral-capsid-antigen-igm-antibodies-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.100683","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,3]]}}}